patent.fyi
Applications  /  US 2026/0355317
United States Patent Application Publication

US 2026/0355317 A1

Published
Nov 12, 2026
Filed
Aug 2, 2023
Earliest date on the face
Aug 3, 2022
Classification
A61K 40/31
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Antibody tether for the tag

What ifWhat if an antibody fragment held the recognition tag on the tumor cell surface?
Claim language“providing a sortase”

An antibody fragment fused to a peptide tag binds an extracellular domain of a tumor surface protein. The exposed peptide tag provides a binding site for the receptor on the administered immune cells.

1.1Reversible capture of the tag

What ifWhat if a nucleic acid aptamer displayed the recognition tag through reversible binding to a tumor surface protein?
Claim language“cells in the tumor are sortagged”

A chemically stabilized aptamer binds an extracellular domain of a tumor surface protein. A spacer holds the attached peptide tag away from the bound aptamer so the immune cell receptor can engage it.

1.2Peptide recognition through a TCR

What ifWhat if the engineered immune cells expressed a T cell receptor that recognized a peptide from the supplied antigen?
Claim language“a chimeric antigen receptor (CAR)”

Tumor cells internalize and process the supplied protein antigen and display a derived peptide on a compatible class I major histocompatibility molecule. Engineered T cells recognize the resulting peptide–molecule complex through their T cell receptor and release cytotoxic granules.

1.2Natural killer cells with antibody

What ifWhat if expanded natural killer cells recognized tagged tumor cells through an antibody and their native Fc receptor?
Claim language“genetically engineered immune cells”

An antibody binds the exposed tag through its antigen-binding arms and engages the native Fc receptor CD16 on the administered natural killer cells. Receptor clustering triggers release of cytotoxic granules toward the antibody-coated cell.

1.2Receptor recognition through an adapter

What ifWhat if the CAR bound a separate soluble adapter that bridged the immune cell to the displayed antigen?
Claim language“capable of binding the exogenous antigen”

The adapter has an antigen-binding arm and a separate peptide that serves as the CAR binding site. The arm captures displayed antigen on the tumor cell, and the peptide recruits the CAR-expressing immune cell.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Fab module for peptide recognition

A two-chain antigen-binding fragment replaces the single-chain variable fragment in the chimeric receptor. The fragment's heavy-chain portion connects to the receptor hinge and membrane anchor, while the separately expressed light chain pairs with it at the cell surface. The assembled binding site recognizes the synthetic peptide displayed on sortase-tagged target cells.

Parameter or scale variation

Three tag densities on model targets

Three populations of model target cells carry low, intermediate, and high surface densities of the same synthetic antigen. Calibrated fluorescence measurements identify populations whose median tag densities have an approximate ratio of 1 to 3 to 10. Each population is combined with receptor-bearing cells at a 1 to 1 cell ratio. A common assay endpoint measures how reporter activation varies with tag density.

Combination with existing systems

Perfused chip for tumor spheroids

A microfluidic culture chip holds a tumor spheroid in a chamber adjacent to a perfusion channel. Sortase and the synthetic antigen conjugate enter through the channel, and a wash removes unbound conjugate before receptor-bearing cells enter through the same channel. Time-lapse microscopy records receptor-bearing cell entry into the spheroid and changes in tumor cell viability.

Membrane insert assay for contact dependence

A porous membrane insert divides a culture well into compartments that share soluble medium while retaining cells. Sortase-tagged target cells occupy the lower compartment, and receptor-bearing immune cells occupy the insert. A paired well places both cell populations in direct contact. Target viability in both wells and soluble signaling markers in the shared medium provide readouts of contact-dependent activity.

Automated or data-driven variant

Image gated addition of receptor cells

An automated microscope measures surface tag fluorescence in wells containing sortase-treated tumor cultures and in paired untagged control wells. Software segments the target cells and calculates the fraction with fluorescence above a threshold derived from the controls. A liquid handler adds a fixed number of receptor-bearing cells when the tagged fraction reaches a preset acceptance value. The system records the measured fraction and dispensing time for each well.

Specific version of a part

Lipid anchor for the tag

A hydrophilic spacer connects the recognition tag to a phospholipid anchor. After local delivery into an accessible tumor, the lipid tails insert into cell membranes and the spacer presents the tag to immune cells.

C terminal sortase donor motif

A recombinant tag protein carries a C-terminal LPETG sequence downstream of its recognition epitope. Sortase cleaves between the threonine and glycine and transfers the tag protein to a surface acceptor with an exposed N-terminal oligoglycine.

Antibody localized sortase acceptor

A tumor-binding antibody fragment carries an exposed N-terminal triglycine acceptor. The fragment binds a tumor surface protein, where sortase couples the recognition tag to the acceptor.

Antibody fragment for tag recognition

A single-chain antibody fragment recognizes the displayed peptide tag. A flexible linker joins the antibody variable domains, and a hinge connects the fragment to the CAR transmembrane segment.

Second generation receptor signaling

Primary T cells express a tag-binding receptor with intracellular 4-1BB and CD3 zeta signaling domains. Engagement with the surface tag clusters the receptor and activates T cell signaling and cytotoxic granule release.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2019/0343880 A1
Published
Nov 14, 2019
Filed
Dec 6, 2017
Class
A61K 35/17
Document BUS 2021/0347845 A1
Published
Nov 11, 2021
Filed
Oct 12, 2019
Class
C07K 14/705
Claim 1
Document A
Document B
1.1providing a sortase and an exogenous antigen to the tumor, wherein the exogenous antigen comprises an exogenous antigen ligand and a sortag motif, and wherein cells in the tumor are sortagged by the exogenous antigen, and
The cytotoxicity of Srt.bbz and Srt.28z was compared in a cell killing assay using Her2+SKOV3 cells that were incubated with Her2-scFv and then washed to remove excess scFv (i.e. preloaded). The SIR-T cells were then added at two different E:T ratios, which demonstrated a higher percent lysis of the SKOV3 cells by the Srt.bbz cells versus the Srt.28z (FIG. 8B).
B · US 2021/0347845 A1 · ¶ 243
1.2administering a therapeutically effective amount of genetically engineered immune cells that express a chimeric antigen receptor (CAR) comprising an antigen binding domain that is capable of binding the exogenous antigen.
As a result of introducing CD19-specific CAR genes into T cells collected from the patients, culturing and proliferating the cells, and infusing them into the patients' bodies, molecular biological remission in the bone marrow was obtained in all 5 cases (see, for example, NPL 2).
A · US 2019/0343880 A1 · ¶ 3
In one aspect, the method comprises administering to a subject in need thereof a therapeutically effective amount of a composition comprising an engineered T cell comprising a sortase CAR.
B · US 2021/0347845 A1 · ¶ 175

An empty cell means only that no passage was reproduced there.

Statements in these documents
In particular, the present invention relates to a chimeric antigen receptor gene-modified lymphocyte capable of exerting a cytocidal effect on a highly EPHB4 receptor (Ephrin type-B receptor 4) expressing tumor, use thereof, and the like.
A · US 2019/0343880 A1 · ¶ 1
This process has been utilized by research groups to incorporate site-specific moieties and functional groups on the cell surface of eukaryotic cells in ways that cannot be produced by genetically modifying the cell.
B · US 2021/0347845 A1 · ¶ 2
Multiple moieties can be attached to a cell surface in predefined proportions based on their stoichiometry.
B · US 2021/0347845 A1 · ¶ 2
Cite aspatent.fyi, US 2026/0355317 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355317/, SHA-256 ede52610d667ad656d1684073098ca8b56690140766c30025caf4129abd6cd72
First published
Permanent addresshttps://patent.fyi/US20260355317/
Content fingerprint (SHA-256)ede52610d667ad656d1684073098ca8b56690140766c30025caf4129abd6cd72
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi